US FDA grants Fast Track designation to Solid Biosciences' SGT─501, an AAV─based l gene therapy to treat ...
Solid Biosciences Inc., a clinical stage life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced that it received Fast Track designation from the US Food and Drug Administration (FDA) for SGT-501, the …